A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors.

Authors

Meredith McKean

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

Meredith McKean , John D. Powderly , Meghan Duncan , Teleen Norman , Ekta Patel , Jennifer O'Neil , George Lee , Katarina Luptakova , Howard E. Kaufman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.

First Author: Paolo Antonio Ascierto

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.

First Author: Carlos A. Gomez-Roca

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.

First Author: J. Eva Selfridge

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors.

First Author: Alexander Starodub